BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1127@pharmaconomics
DTSTAMP:20260707T021625Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ANNX PDUFA — tanruprubart (estimated date)
DESCRIPTION:The FDA's approval decision on tanruprubart for Guillain-Barré Syndrome (GBS) is due ~ Dec 31\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1528115/000119312526131746/annx-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/1127
URL:https://pharmaconomics.com/e/1127
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ANNX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR